Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Arrhythmia

Interventions

DRUG: GAP-486 (ZP-123)
DRUG: 0.9% Sodium Chloride, USP

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer